Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 25;8(1):43-47.
eCollection 2020.

Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer

Mozhde Askari  1 , Amid Yazdani  1 , Mohammad Yazdani  2 , Mohammad Hossein Izadpanahi  2
Affiliations

Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer

Mozhde Askari et al. Am J Clin Exp Urol. .

Abstract

Background: Urine test with the PSA result will provide a good prognosis of the prostate cancer. Therefore, considering the importance of PCA3 in this study, we aimed to compare the serum total and urinary PCA3 levels in patients with benign hyperplasia and prostate cancer.

Methods: This cross-sectional study was performed on 90 patients referring to Noor and Hazrat-e-Ali Asghar Hospital in Isfahan from October 2017 to October 2018 for prostate biopsy. Patients were divided into two groups including benign prostate hyperplasia (BPH) and prostate cancer. Serum total and urinary PCA3 levels were measured and compared in both groups.

Results: 38 patients with prostate cancer and 52 patients with BPH participated in this study. Mean age in prostate cancer group was significantly higher than BPH group (P=0.01). Also mean PCA3, and total PSA, in patients with prostate cancer was significantly higher than patients with BPH (P<0.05).

Conclusion: PCA3 was an important marker in patients with prostate cancer and BPH.

Keywords: Urine test; benign prostate hyperplasia; markers; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
ROC curve of PCA3.
Figure 2
Figure 2
ROC curve of PSA.
See this image and copyright information in PMC

References

    1. Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, Gunnlaugsson A, Widmark A, Van Hemelrijck M. Prostate cancer radiation therapy and risk of thromboembolic events. Int J Radiat Oncol Biol Phys. 2017;97:1026–1031. - PubMed
    1. Alavi A, Izadpanahi MH, Haghshenas L, Faridizad R, Eslami MJ, Ghadimi K. Comparing urine levels of BLCA-4 nuclear matrix protein in patients with bladder cancer and non-bladder cancer. Int J Physiol Pathophysiol Pharmacol. 2019;11:289–292. - PMC - PubMed
    1. Hosseini J, Fallah-Karkan M, Rahavian A, Soleimanzadeh F, Salimi H, Ghadimi K, Fahim M. Feasibility, complication and long-term follow-up of the newly nelaton based urethral dilation method, retrospective study. Am J Clin Exp Urol. 2019;7:378–383. - PMC - PubMed
    1. Pyo JS, Cho WJ. Systematic review and meta-analysis of prostatic artery embolisation for lower urinary tract symptoms related to benign prostatic hyperplasia. Clin Radiol. 2017;72:16–22. - PubMed
    1. Han Z, Zhang L, Zhu R, Luo L, Zhu M, Fan L, Wang G. Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men. Medicine (Baltimore) 2017;96:e6473. - PMC - PubMed

LinkOut - more resources